Sort
16,300 grants matching “fatty liver disease”
Modulators of HDL Structure-Function
$433,550G M Anantharamaiah · University Of Alabama At Birmingham · P01 · FY2008 · HL
Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention
$433,515Ruth Lupu · Mayo Clinic Rochester · R01 · FY2013 · CA
Role of phospho UBC9 in alcohol-associated liver disease
$433,445Maria Lauda Tomasi · Cedars-Sinai Medical Center · R01 · FY2024 · AA
Role of TAZ in metabolic regulation in both normal and insulin resistant states
$433,398Ji Miao · Boston Children'S Hospital · R01 · FY2024 · DK
Control of stellate cells-driven liver cancer by the p62/NBR1 adapters
$433,352Jorge Moscat · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2018 · DK
Control of stellate cells-driven liver cancer by the p62/NBR1 adapters
$433,352Jorge Moscat · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2019 · DK
Control of stellate cells-driven liver cancer by the p62/NBR1 adapters
$433,352Jorge Moscat · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2017 · DK
Placental adiponectin signaling and fetal programming in maternal obesity
$433,243Thomas Jansson · University Of Colorado Denver · R01 · FY2018 · HD
TIM-4 Signaling in NASH Liver Transplant Ischemia/Reperfusion Injury
$433,125Haofeng Ji · University Of California Los Angeles · R21 · FY2025 · AI
HDL, Inflammation and Atherosclerosis
$433,121Alan Chait · University Of Washington · P01 · FY2010 · HL
A novel CREBH-derived hepatokine regulates triglyceride metabolism
$432,970Kezhong Zhang · Wayne State University · R01 · FY2023 · DK
Control of glucose homeostasis through the insulin-independent Isthmin pathway
$432,630Katrin Jennifer Svensson · Stanford University · R01 · FY2024 · DK
Epigenetic dysregulation of transposons in obesity
$432,500Dustin Edward Schones · Beckman Research Institute/City Of Hope · R01 · FY2019 · DK
Modified Intestinal apoAI-particles and Lymphatics Accelerate CKD-driven CVD
$432,500Valentina Kon · Vanderbilt University Medical Center · P01 · FY2021 · HL
Epigenetic dysregulation of transposons in obesity
$432,500Dustin Edward Schones · Beckman Research Institute/City Of Hope · R01 · FY2018 · DK
Epigenetic dysregulation of transposons in obesity
$432,500Dustin Edward Schones · Beckman Research Institute/City Of Hope · R01 · FY2020 · DK
Epigenetic dysregulation of transposons in obesity
$432,500Dustin Edward Schones · Beckman Research Institute/City Of Hope · R01 · FY2017 · DK
Modified Intestinal apoAI-particles and Lymphatics Accelerate CKD-driven CVD
$432,500Valentina Kon · Vanderbilt University Medical Center · P01 · FY2023 · HL
Therapeutic Potential of Estrogen-Regulated Metabolism and Cardiovascular Risk
$432,500John Micheal Stafford · Vanderbilt University Medical Center · R01 · FY2021 · DK
Modified Intestinal apoAI-particles and Lymphatics Accelerate CKD-driven CVD
$432,500Valentina Kon · Vanderbilt University Medical Center · P01 · FY2022 · HL
Epigenetic dysregulation of transposons in obesity
$432,500Dustin Edward Schones · Beckman Research Institute/City Of Hope · R01 · FY2021 · DK
GENE THERAPY FOR DYSLIPIDEMIAS
$432,414Daniel James Rader · University Of Pennsylvania · P01 · FY2010 · HL
Regulation of Liver Growth and Function
$432,352Leonard S Jefferson · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2008 · DK
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR
$432,304Gerardo M. Castillo · Pharmain Corporation · R44 · FY2011 · AA
Rho-kinase signaling in energy balance
$432,250Young-Bum Kim · Beth Israel Deaconess Medical Center · R01 · FY2024 · DK